GlobeNewswire by notified

Memo Therapeutics AG appoints Paul Carter as Chairperson



Memo Therapeutics AG appoints Paul Carter as Chairperson

  • Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV
  • Extensive public and private market experience following executive positions in numerous biopharma companies

Schlieren / Zurich, Switzerland, 8July, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors.

Paul has had an extensive executive career in the biopharma space, with commercial and M&A expertise spanning North America, Europe, and Asia. He has over 10 years of experience working in the virology field at Gilead Sciences Inc., most recently as EVP and Chief Commercial Officer, where he oversaw over $30 billion dollars of sales and contributed to multiple M&A transactions. Prior to this, he spent seven years at GlaxoSmithKline (“GSK”), where he was responsible for all GSK interests in the Greater China region.

Paul will replace Elias Papatheodorou, who was instrumental in the transition of MTx from a preclinical-stage to a well-funded clinical-stage company with an experienced and well-rounded management team. Elias is transitioning into an executive role at a European biotech and will hand-over to Paul as part of a planned succession process.

Erik van den Berg, CEO of MTx, commented: “We are delighted to welcome Paul Carter as our Chairperson. Paul’s track record and commercial and M&A expertise make him a perfect addition to our team. We look forward to his advice and support in driving the Company’s continued success as we advance into a Phase III ready organization. To Elias, we extend our gratitude for his significant contributions to our company, culminating in our recently closed Series C financing.”

Paul Carter, incoming Chairperson at MTx, added: “I am thrilled to be taking on this role at such a pivotal stage in MTx’s development. The Company’s AntiBKV program shows tremendous promise, with Phase III trials fast approaching. BKV remains a significant unmet need and I look forward to working closely with the Board and management team on realizing AntiBKV’s potential for kidney transplant patients worldwide.”

Following his successful career as an executive, Paul is now focused on his Board and retained Advisory roles. He is currently a Board Member for a wide range of public companies including HutchMed (Nasdaq/AIM:​HCM; HKEX:​13) and Immatics (Nasdaq:IMTX), and has held prior Board roles at Alder BioPharmaceuticals (Nasdaq:ALDR), acquired by Lundbeck (CPH:HLUN-A) for $2 billion, and VectivBio (Nasdaq:VECT), acquired by Ironwood Pharmaceuticals (Nasdaq: IRWD) for $1 billion.

In May, MTx announced that it had raised an additional CHF 20 million, bringing in new investors Kurma Partners and Ysios Capital and increasing its Series C financing to CHF 45 million.


Memo Therapeutics AG
ICR ConsiliumAmber Fennell, Ashley Tapp (0)20 3709 5700

About Memo Therapeutics AG
Memo Therapeutics AG (“MTx”) is a late-stage biotech company translating unique immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company’s lead program, AntiBKV, is in Phase II development targeting BK viremia in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. AntiBKV has the potential to become the best and first-in-class BKV disease-modifying therapy for kidney transplant patients with a market potential of more than $1bn.

Alongside AntiBKV, MTx is focused on discovering antibodies for novel oncology targets, both alone and in partnership. The Company has a partnership in place with Ono Pharmaceutical since late 2022. Underpinning MTx’s core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high- throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital. Learn more at, and on LinkedIn.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release

Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a

DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release

Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68

Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release

Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email

Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release

AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us

Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release

VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin

HiddenA line styled icon from Orion Icon Library.Eye